The 10AT-Her2 cell system provided the experimental opportunity directly to test the hypothesis that cellular components that help define the cancer stem/progenitor character, such as nucleostemin, can confer selective responsiveness of anti-cancer compounds to target breast cancer stem/progenitor populations. The gene discussed is ERBB2; the disease is cancer.